THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the company”) Destiny Pharma […]
What to wear during cancer treatment: dressing for comfort & practicability Cancer treatment can go on for months or even years for some people. That’s certainly a long time to wear flimsy and uncomfortable hospital gowns or struggle with unsuitable clothing during chemotherapy, radiotherapy or after surgery. When it comes to finding the best clothes […]
Tuesday, April 3, 2018 6:50 am EDT SAN DIEGO PUBLIC COMPANY INFORMATION: NYSEAM: APHB “Additionally, we were able to stop his cycles of recurrent pseudomonal pneumonia and observed re-establishment of commensal respiratory flora. Based on my experience, phage therapy warrants further clinical investigation and is a promising treatment modality for patients suffering from severe and […]
San Mateo, CA – March 27, 2018: Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, today announced the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for over-the-counter (OTC) sales of its SmartinhalerTM sensor for AstraZeneca’s Symbicort® aerosol asthma inhaler. The Smartinhaler sensor is a device installed onto a […]
Soap and glory for Irish entrepreneur Deborah Neill We’re always on the lookout for new, innovative, and most importantly helpful products to add to our growing catalogue. A new addition to our site is Deborah Neill Handmade Soap, beautiful handmade soap created by a cancer survivor to help soothe irritated skin that has been affected by cancer treatment. Here, soapmaker […]
CATEGORY: Featured Tuesday, March 20, 2018 8:00 am EDT SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has entered into definitive purchase agreements with certain institutional investors to sell in a registered […]
Also Announces that Major Hospital Will Host New Training Center for RECELL in Beijing Valencia, CA, USA, and Melbourne, Australia, 19 March 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced the commencement of a randomized, controlled clinical trial of RECELL® in the treatment of deep partial-thickness (second-degree) burns in China. RECELL is a medical […]
CATEGORY: Featured Monday, March 19, 2018 4:10 pm EDT SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB “The promising clinical results I have observed to-date support the potential of bacteriophage therapeutics to be a safe and potent adjunct treatment for serious bacterial infections.” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company […]
Posted on 15/03/2018 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) […]
Announced positive topline results for the first seven patients treated with AB-SA01 or AB-PA01 under ongoing expanded access program. Treatment was well tolerated with 86% of patients achieving treatment success Signed a Cooperative Research and Development Agreement with the U.S. Department of Veterans Affairs Completed a public offering of common stock in Jan. 2018 for […]